AMPH (Amphastar Pharmaceuticals) Growth Rank: 10 (As of Jul. 25, 2026) — 43% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AMPH Amphastar Pharmaceuticals Inc AMPH
84 GF Score
Price $18.71
GF Value $49.03
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Amphastar Pharmaceuticals Growth Rank?

Amphastar Pharmaceuticals AMPH -0.79% 84 Growth Rank is 10 as of Jul. 25, 2026, which is 43% above its 10-year median of 7.00. GuruFocus rates AMPH with a GF Score™ of 84/100 and a GF Value™ of $49.03 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Amphastar Pharmaceuticals has the Growth Rank of 10.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Amphastar Pharmaceuticals Growth Rank Related Terms

AMPH vs ETON, PCRX, BIOA: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amphastar Pharmaceuticals Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Growth Rank distribution charts can be found below:

* The bar in red indicates where Amphastar Pharmaceuticals's Growth Rank falls into.


AMPH
84GF Score
Amphastar Pharmaceuticals Inc AMPH
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 10 mean?
Amphastar Pharmaceuticals (AMPH) has a Growth Rank of 10 as of Jul. 25, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Amphastar Pharmaceuticals and its competitors. This is 43% above median its historical median of 7.00. Over the past decade, Amphastar Pharmaceuticals' Growth Rank has ranged from 1.00 to 10.00.
Is Amphastar Pharmaceuticals' Growth Rank too high?
Amphastar Pharmaceuticals' current Growth Rank of 10 is 43% above median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Amphastar Pharmaceuticals has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' Growth Rank compare to ETON and PCRX?
Amphastar Pharmaceuticals' Growth Rank of 10 can be compared against companies in the Drug Manufacturers industry. Historically, Amphastar Pharmaceuticals' own Growth Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Amphastar Pharmaceuticals and its competitors. Amphastar Pharmaceuticals's current Growth Rank is 10, which is 43% above median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $49.03, compared to a current price of $18.71 — trading 61.8% below its estimated fair value. The current Growth Rank is 10, which is 43% above median its 10-year median of 7.00. Amphastar Pharmaceuticals' overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current Growth Rank is 10 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?

Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued. The current stock price of $18.71 is trading 61.8% below its estimated GF Value™ of $49.03. GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for AMPH:

  • Growth Rank: 10 (43% above median its 10-year median of 7.00)
  • GF Value™: $49.03 vs. price of $18.71 (61.8% below fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amphastar Pharmaceuticals Business Description

Other Exchanges 29A:Germany
Address 11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
84GF Score

Get the complete analysis for AMPH

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.71
Price
$49.03
GF Value